"Phoenix WinNonlin version 6.0 merges the trusted algorithms from WinNonlin with new powerful data management tools and high-quality graphics to support comprehensive PK/PD analysis.
"The release of Phoenix WinNonlin represents an important milestone in Pharsight's vision for software to enable model-based drug development and its utility in translational science," said Daniel Weiner, Ph.D., senior vice president and chief technology officer of Pharsight. In addition to the release of Phoenix WinNonlin 6.0, newly released Phoenix Connect TM software integrates applications built on the Phoenix platform with commonly used third-party analysis and modeling tools such as S-PLUS®, NONMEM® and SAS®, and enables data import/export with emerging industry standards such as CDISC. Phoenix WinNonlin will continue to operate with Pharsight's enterprise PK/PD data management system, Pharsight Knowledgebase Server TM (PKS TM), and can also be used independently of PKS. Phoenix WinNonlin will be backward-compatible with WinNonlin versions 4 and 5. The major features of Phoenix WinNonlin 6.0 include a new graphical user interface that makes creation and re-use of PK/PD analysis workflows seamless and intuitive, powerful native graphics and improved data management tools. Phoenix WinNonlin 6.0 is the cornerstone of Phoenix TM, Pharsight's new desktop software platform that is designed to advance model-based drug development by providing an integrated environment for data analysis, modeling and simulation. LOUIS - Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, today announced the launch of Phoenix WinNonlin, the next generation of the company's industry-standard software tool for pharmacokinetic and pharmacodynamic (PK/PD) modeling and noncompartmental analysis. Phoenix WinNonlin 6.0 Provides Enhancements to Industry-Standard PK/PD Analysis Tool, Adds New Interface and Workflow Management Engine
Pharsight Launches Phoenix WinNonlin as Cornerstone of New Software Platform for Model-Based Drug Development
0 kommentar(er)
